AtriCure, Inc. Overview
Pro stress-test →AtriCure develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. The company serves electrophysiologists and cardiothoracic surgeons with solutions for treating atrial fibrillation, a condition affecting over 59 million people worldwide.
Strategic Profile
Pro stress-test →AtriCure's AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. Accelerated adoption of innovative minimally invasive devices and successful product launches are driving strong revenue growth, profitability, and operating leverage, with global market expansion, advancing clinical trials, and robust evidence generation broadening access and supporting payer acceptance.
Competitive Landscape
Pro stress-test →AtriCure operates in the surgical ablation and cardiac device market alongside competitors offering catheter-based and drug-based alternatives for atrial fibrillation treatment. The company's differentiation lies in minimally invasive surgical approaches with proprietary devices like Isolator Synergy, hybrid AF therapy, and AtriClip systems that have achieved significant market adoption among cardiothoracic surgeons and electrophysiologists globally.
Industry Context
AtriCure, Inc. operates in Medical Devices - Cardiac Surgery/Electrophysiology.
Key facts
Founded: 2000 · Headquarters: Mason, US · Employees: 1,300 · Revenue: $465.3M